Federal Circuit Denies Amgen's Rehearing Request
In a setback for drug maker Amgen Inc., the U.S. Court of Appeals for the Federal Circuit has rejected the drug maker's request that it reconsider a patent infringement ruling partially...To view the full article, register now.
Already a subscriber? Click here to view full article